Anne Wojcicki’s Quest to Put People in Charge of Their Own Health
By Stephanie Lee,
San Francisco Chronicle
| 02. 28. 2015
[Quotes CGS's Marcy Darnovsky]
[The following is an excerpt. Access the full article here.]
Wojcicki (pronounced wo-JIT-ski) made it her mission to upend health care. In 2006, she co-founded 23andMe, a Silicon Valley company out to pool the world’s DNA, give individuals access to their genetics, and in the process transform the way drugs are made, diseases are cured and patients are treated. In that crowd is her husband, Google co-founder Sergey Brin, who learned from 23andMe that he has a genetic mutation putting him at high risk for Parkinson’s disease.
“To be able to answer thousands and thousands of questions,” she said, “you want tons and tons of data.”
So far, 23andMe has attracted nearly 1 million customers and more than $126 million in venture capital, making it one of the most hyped health-technology firms in the world — and its CEO one of the most influential women in tech.
But not everyone thinks Wojcicki should be the one to collect their data...
“They’ve had a very intense marketing campaign that’s made a lot of bold claims, both about the...
Related Articles
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...